Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 36Terminated 12Unknown 9Withdrawn 5Recruiting 5Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 5NIH 2INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 2Myeloid 2Dermatologic 1

Conditions

Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Neoplasms 1Neoplasm Metastasis 1Melanoma 1

Interventions

Specimen Handling 336Magnetic Resonance Spectroscopy 333Radiotherapy 315Cyclophosphamide 295pembrolizumab 282Cisplatin 266Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 206Bevacizumab 187Gemcitabine 177venetoclax 172Radiosurgery 169Capecitabine 165Oxaliplatin 163fludarabine 160Nivolumab 156Paclitaxel 155Standard of Care 137Surveys and Questionnaires 131Surgical Procedures, Operative 130Dexamethasone 127Fluorouracil 125Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104atezolizumab 101Azacitidine 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × OTHER × nilotinib × Clear all
NCT04903119 2026-02-13

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

University of Kentucky

Phase 1 Recruiting
30 enrolled
Dermatologic

Melanoma

NCT02029001 2025-08-07

MOST plus

Centre Leon Berard

Phase 2 Recruiting
900 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Medical College of Wisconsin

Phase 2 Recruiting
51 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06409936 2025-07-08

PEARL

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Recruiting
160 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡